Figure 5.

Cumulative incidence for use of a third-line ART regimen using death and loss to follow-up as competing events by first regimen treatment group (efavirenz vs boosted protease inhibitor). Abbreviations: bPI, boosted protease inhibitor; EFV, efavirenz; LTFU, lost to follow-up, defined as no visits in the year before the closing date of data set in each site; Third-line, use of a third-line regimen, defined as (1) 2 previous ART regimen changes due to treatment failure and at least 1 of these drugs in the selected third regimen, etravirine, raltegravir, maraviroc, tipranavir, dolutegravir, or darunavir; or (2) 1 previous ART regimen change due to treatment failure and the use of at least 2 of the above-mentioned drugs in the selected third regimen.